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Periodontitis is a chronic inflammatory disease that infects the tissues of the 
periodontium. It is estimated that 47.2% or 67.2 million American adults 
suffer from mild, moderate and severe periodontitis. Globally, 30-50% of the 
adult population is afflicted with periodontal disease, making it one of the 
most prevalent infectious diseases in the world. Therapeutics targeting P. 
gingivalis may be effective to alter periodontitis progression. However, the 
current treatment modalities that target critical pathogens to maintain host-
biofilm homeostasis are limited, urging the development of specifically 
targeted therapeutics to limit P. gingivalis recolonization of the oral cavity 
after periodontal treatment and healing. We previously identified a peptide 
(BAR) that inhibits the formation of P. gingivalis-S. gordonii biofilms; 
however, formulations that effectively deliver the peptide within the oral 
cavity are lacking. Polymeric electrospun fibers (EFs) offer a new platform 
to deliver high localized concentrations of the peptide (BAR) for prolonged 
periods, to disrupt established biofilms and enhance BAR effectiveness. The 
 
v  
objective of this study was to determine if electrospun fibers (EFs) that 
encapsulate the BAR peptide, function as a sustained-release drug delivery 
vehicle for application in the oral cavity. A variety of polymer formulations 
were electrospun using a uniaxial electrospinning approach. Polymers 
including poly(lactic-co-glycolic acid) (PLGA) or methoxy-poly(ethylene 
glycol) (mPEG-PLGA), polycaprolactone (PCL), and poly(L-lactic acid) 
PLLA, were synthesized alone or blended in a 40:60, 20:80 and 10:90 w/w 
ratio with a hydrophilic polymer, polyethylene oxide (PEO), to increase BAR 
release over 24 hr. To determine the total loading of BAR in EFs, the fibers 
were dissolved in DMSO, and the amount of BAR encapsulated was 
compared to a known standard of fluorescently-labeled BAR (F-BAR). The 
sustained-release of F-BAR from fibers was determined by comparing the 
supernatant from a variety of release time points to a known standard of F-
BAR. PLGA, mPEG-PLGA, PCL and PLLA EFs demonstrated 
encapsulation efficiencies of 68%, 94% 60% and 46% respectively, while 
exhibiting minimal release of BAR (9.5%, 7%, 1.4% and 1.5%) within 24 hr. 
Blended polymeric fibers comprised of PLGA:PEO, PCL:PEO, and 
PLLA:PEO with 40:60, 20:80 and 10:90 w/w ratios were fabricated to 
enhance release. All polymer blends incorporated high concentrations of 
BAR peptide, and increasing ratios of PEO significantly enhanced BAR 
release within 24 hr. The most promising 10:90 PLGA:PEO, PCL:PEO, and 
PLLA:PEO formulations provided 95%, 50% and 75% BAR release at 4 hr.
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Periodontal diseases are highly prevalent and can affect up to 90% of the 
worldwide population. Gingivitis, the mildest form of periodontal disease, is 
caused by the bacterial biofilm (dental plaque) that accumulates on teeth 
adjacent to the gingiva (gums) (Pihlstrom, Michalowicz, & Johnson, 2005). 
The colonization of bacteria in the supragingival area initiates an 
inflammatory response (Brogden & Guthmiller, 2002; Dickinson et al., 
2011) and gingivitis, if left untreated, can lead to a more severe form of 
periodontal disease characterized by clinical attachment loss, termed 
periodontitis (Heijl et al., 1976). Periodontitis is a chronic, irreversible 
inflammatory disease, during which the chronic infiltrate of immune cells 
induces destruction of connective tissue, vascular proliferation and alveolar 
bone destruction (Pihlstrom, Michalowicz & Johnson, 2005). Periodontitis is 
second only to dental caries as a cause of tooth loss among adults in 
developed countries (Gautam et al., 2011). 30-50% of the global adult 
population suffers from periodontal disease making it one of the most 
prevalent infectious diseases in the world. It is estimated that 47.2% or 67.2 
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million American adults suffer from mild, moderate and severe periodontitis 
(P.I Eke et al., 2012). Severe disease (subgingival pocket depths > 6mm) 
occurs in 9% of U.S. adults (Adeyemi et al, 2015) and 11.2% of adults 
worldwide (Eke, P., et al. 2012, Kassebaum et al, 2014). This correlates to 
annual expenditures for the treatment and prevention of periodontal disease 
in excess of 14 billion dollars (Eke, P., et al. 2012). Other studies have also 
demonstrated that mild forms of periodontitis affect 75% of adults in the 
United States and more severe forms affect 20 to 30% of adults (Dhadse et 
al, 2010). Periodontal diseases are also proven to be risk factors for various 
systemic diseases such as bacteremia, infective endocarditis, cardiovascular 
disease, prosthetic device infection, diabetes mellitus, respiratory diseases, 
rheumatoid arthritis and adverse pregnancy outcomes (Kim et al, 2006, 
Scannapieco et al, 2013, Kaur et al 2014). 
 
Dental plaque biofilm formation 
A biofilm is an organized aggregate of microorganisms living within an 
extracellular polymeric matrix that they produce and irreversibly attach to 
fetish or living surface which will not remove unless rinse quickly (Hurlow 
et al., 2015). The National Institutes of Health (NIH) revealed that among all 
microbial and chronic infections, 65% and 80%, respectively, are associated 
with biofilm formation (Jamal et al., 2018). Microbial biofilms are known to 
cause a number of infectious diseases in humans, a few of which include 
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tonsillitis, dental disease, urinary tract infections and endocarditis. The oral 
cavity is a dynamic environment and from a biofilm-formation standpoint, 
the oral cavity is a propitious environment that allows for the growth of a 
diverse array of microorganisms (Gibbons, 1989). In periodontal disease, the 
accumulation of biofilm around the gingival margins provokes an 
inflammatory response by the host. This involves an increased flow of 
Gingival Crevicular Fluid (GCF) which not only introduces components of 
the host response but also many molecules that can act as potential nutrients 
for some of the minor components of the normal resident subgingival 
microbiota (Wade, 2013). A small sample of dental plaque contains, on 
average, between 12 and 27 species (Aas, Paster, Stokes, Olsen, & Dewhirst, 
2005) hence dental plaque is a classic example of multispecies biofilm. The 
formation of dental plaque involves several phases within seconds of tooth 
eruption or after tooth cleaning (Diaz et al., 2006). Hence, understanding the 
growth, progression and arrangement of plaque alongside the etiology will 





Development of Dental plaque 
 
Figure 1. Biofilm development 
 
The development of oral biofilms depends on interactions between bacterial 
cell-surface adhesins and host receptors. Interactions between different 
species of bacteria, and between bacteria and the host, are central to the 
development of oral biofilm (Jakubovics & Kolenbrander, 2010). The key 
stages in the development of a biofilm as shown in figure 1 are: first, pellicle 
formation; second, adhesion of a microorganism to a surface and individual 
colonization and organization of cells; third, secretion of extra cellular 
polymeric substances (EPSs) and maturation into a three-dimensional 
structure; and finally, dissemination of progeny biofilm cells (Seneviratne, 






When the bacterial and host products come in contact with a clean tooth 
surface, the negatively charged hydroxyapatite tooth surface absorbs it and 
forms a thin layer of conditioning film called the acquired pellicle 
(Armstrong et al, 1968). In the supragingival areas, this layer is covered by 
positively-charged molecules such as salivary glycoproteins, statherin, 
histatin, proline rich proteins, alpha-amylase, bacterial components like 
glucosyltransferases (GTFs), glucan, and by-products from gingival 
crevicular fluid in the subgingival areas (M. Hannig & Joiner, 2006). Acidic 
phosphoproteins and proline-rich proteins that aid in colonization of bacteria 
on to the tooth surfaces mediate the initial interaction between the pellicle 
and the bacteria. In addition, other environmental cues can influence biofilm 
formation including low pH, changes in osmolarity, and oxygen. The early 
plaque forming bacteria or the initial colonizers are generally Gram-positive 
cocci, which primarily comprise streptococcal species. (Marsh, 1994, 2006). 
 
Adhesion of bacteria to the salivary pellicle represents the second step in the 
colonization of enamel surfaces in the mouth. Oral streptococci such as 
Streptococcus sanguinis, Streptococcus oralis, and Streptococcus mitis have 
been shown to be the major primary colonizers, constituting 60–80% of 
dental plaque within 4 to 8 hr (Diaz et al., 2006). They initially make non-
specific, reversible bonds like hydrogen bonds, hydrophobic interactions, 
calcium bridges, van der Waals forces, acid-base interactions and 
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electrostatic interactions with the molecules in the acquired pellicle (C. 
Hannig & Hannig, 2009; Marsh, 2005).  The main physical surface 
attachment structures of bacteria are fimbriae and fibrils (Donlan, 2002).  The 
pellicle provides a sticky base to support further assemblage of 
microorganisms (Lindh et al, 2014). 
 
Dental plaque biofilm will continue to grow and expand by the multiplication 
of the primary colonizers and co-aggregation and co-adhesion of secondary 
colonizers. Primary colonizers are mostly aerobic or facultative aerobes 
which reduce oxygen, allowing the anaerobic bacteria such as Actinomyces 
species, Fusobacterium nucleatum, Prevotella intermedia, and 
Capnocytophagia species to enter the biofilm community (Seneviratne et al., 
2011). Co-aggregation is driven by specific receptor-ligand interactions that 
allow new bacterial colonizers to adhere to the previously attached cells 
(Grenier, 1992). The fundamental mechanism of aggregation is 
polysaccharide recognition between bacteria. The polysaccharide 
recognition sites vary from one paired bacterial recognition to another paired 
bacterial recognition, because one bacterial cell has several different 
receptors which are complementary to different adhesions belonging to other 




As multiplication of bacteria occurs, discrete colonies of microorganisms are 
formed. These microcolonies secrete extracellular polymeric substances 
(EPS), and get embedded in it, thus providing a physical scaffold for the 
biofilm. A mature biofilm community is formed as the microcolonies 
embedded in EPS become linked together in an organized manner 
(Seneviratne et al., 2011). The mature biofilm is also comprised of fluid filled 
channels interspersed in the microcolonies, which provide nutrients and 
oxygen required for bacterial growth. The final stage of biofilm development 
is the detachment of cells from the biofilm colony and their dispersal into the 
environment, which can be active or passive.  
Active dispersal refers to mechanisms that are initiated by the bacteria 
themselves, which includes modes like seeding dispersal, referring to the 
rapid release of a large number of single cells or small clusters of cells from 
hollow cavities that form inside the biofilm colony (Boles, Thoendel, & 
Singh, 2005). Passive dispersal refers to biofilm cell detachment that is 
mediated by external forces such as fluid shear or abrasion (Lawrence, 
Scharf, Packroff, & Neu, 2002). Modes like erosion, which refers to the 
continuous release of single cells or small clusters of cells from a biofilm, 
and sloughing, referring to the sudden detachment of large portions of the 
biofilm, can be either active or passive processes (Lappin-Scott & Bass, 
2001; Marshall, 1988). 
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Etiology of Periodontitis 
The complex multifactorial etiology of Periodontitis includes genetic 
predisposition along with state of systemic health of the host and 
environmental factors. Several other risk factors including diet, stress, and 
smoking can be involved. At the microbial level, Porphyromonas gingivalis, 
Tannerella forsythia, and Treponema denticola are considered as 
‘periodontopathogens’, and have been classified as ‘red’ complex oral 
bacteria that have are present in the pathogenic dental plaque and have 
strong association with periodontitis (Darveau, Hajishengallis, & Curtis, 
2012; Griffen et al., 2012; Socransky, Haffajee, Cugini, Smith, & Kent, 
1998).  
The role of plaque bacteria in diseased individuals can be explained by two 
main hypotheses. The “non-specific plaque” hypothesis proposed that plaque 
is a conglomerate of multiple microorganisms and that no specific bacteria 
is responsible for the progression of periodontitis (Rosier, De Jager, Zaura, 
& Krom, 2014). In view of this, mechanical therapy for plaque removal was 
considered the best way to curb the disease. Contrary to this, the “specific 
plaque hypothesis” proposed by Loesche purports that out of a diverse 
microbial community in the oral cavity, only specific microorganisms 
belonging to the ‘red’ complex are involved in the etiology of periodontitis 
(Loesche, 1992). While, Porphyromonas gingivalis, Tannerella forsythia, 
and Treponema denticola have strongly been identified with periodontitis, it 
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does not sufficiently elucidate the presence of pathogenic bacteria in healthy 
hosts or the absence of it in diseased individuals (G. Hajishengallis & 
Lamont, 2012). A more recent “keystone pathogen hypothesis” shows P. 
gingivalis, even in low levels, can play a significant role in changing the 
microflora from a symbiotic microbiota to a dysbiotic state, leading to 
disruption of the host-microbe homeostasis (George Hajishengallis, 
Darveau, & Curtis, 2012). Moreover, the recently described Polymicrobial 
Symbiosis and Dysbiosis (PSD) model highlights the importance of other 
microorganisms outside the ‘red’ complex capable in causing dysbiosis (G. 
Hajishengallis & Lamont, 2014). Altogether, a better understanding of the 
complex interactions between the microbes, host and its immunity can help 
discern the etiology.  
 
P. gingivalis and its interaction with Streptococcus gordonii 
As a Gram-negative anaerobic microorganism, P. gingivalis plays a pivotal 
role in periodontitis (Socransky et al., 1998). P. gingivalis has been 
extensively studied, with studies by Hajishengalis et al,2012 recognizing it 
as a keystone pathogen in mice and its relative ease of cultivation and genetic 
modification compared to the other species (Darveau et al., 2012). Prior to 
its colonization in the anaerobic environment of the subgingival pocket, it 
interacts with the initial colonizer Streptococcus gordonii, a Gram-positive 
commensal (Marsh, 1994). Development of biofilm occurs subsequent to the 
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initial adherence of P. gingivalis and S. gordonii deposited on the salivary 
pellicle (Kolenbrander & London, 1993). The ability of  P. gingivalis to 
adhere, grow and retain in different areas is  through adhesins including 
fimbriae, hemagglutinins and proteinases (Lamont & Jenkinson, 2000). The 
commensal species S. gordonii also provides an attachment substrate for 
biofilm establishment by P. gingivalis (Park, Y. et al., 2005).  
 
To limit and inhibit biofilm formation, these distinct adhesion mechanisms 
can be targeted by therapeutic agents to curtail periodontal disease (Carlo 
Amorin Daep, DeAnna M. James, Richard J. Lamont, & Donald R. Demuth, 
2006). S. gordonii expresses the antigen I/II proteins, which are 
multifunctional adhesins, and contribute to the initiation and development of 
the oral biofilm (Demuth & Irvine, 2002). The SspA and SspB polypeptides, 
members of the antigen I/II, adhere to the minor fimbrial antigen (Mfa) of P. 
gingivalis. A previous study by (Brooks, Demuth, Gil, & Lamont, 1997) 
showed the region defined by amino acid residues 1167 to 1250 of the SspB 
polypeptide sequence is essential for adherence to P. gingivalis. Further 
studies demonstrated that a protein determinant comprised of amino acids 
1167 to 1193 designated as BAR (SspB Adherence Region) was sufficient to 
interact with P. gingivalis (Demuth, Irvine, Costerton, Cook, & Lamont, 
2001). A synthetic peptide comprised of this sequence potently inhibited the 
protein-to-protein interactions between P. gingivalis and S. gordonii. But 
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asacchrolytic bacteria like P. gingivalis utilizes amino acids as their energy 
sources making it highly proteolytic in nature. This makes the BAR peptide 
susceptible to degradation. Study by Daep, et al. showed the inclusion of the 
BAR’s receptor Mfa protein into P. gingivalis cell extracts can prevent the 
BAR peptide’s degradation. This suggests the affinity of BAR for Mfa1 is 
greater than for the proteases secreted by P. gingivalis. This overcomes the 
problem of BAR’s susceptibility to degradation and hence can be utilized as 
a potential therapeutic agent as it inhibits P. gingivalis adherence to 
streptococci in the presence of proteolytic enzymes (Daep, Novak, Lamont, 
& Demuth, 2010). In vitro experiments confirmed BAR inhibition of the 
resultant formation of biofilms (IC50 = 1.3µM) (C. A. Daep, D. M. James, 
R. J. Lamont, & D. R. Demuth, 2006). BAR inhibited P. gingivalis virulence 
in mice when administered simultaneously with P. gingivalis infection, in 
vivo (Daep, Novak, Lamont, & Demuth, 2011). Though BAR showed great 
ability to inhibit and prevent the initial interaction between P. gingivalis and 
S. gordonii, in vitro results exhibited weaker potency against already 
established and complex biofilms. Moreover, BAR administration 
demonstrated transient effects. In this study, we developed electrospun 
fibers, a new delivery platform to utilize and administer BAR more 




Nanotechnology in therapeutics 
The presence of a diverse and complex microflora in the oral cavity can make 
periodontitis a difficult disease to treat. Various mechanical therapies like 
scaling and root planning fail to eradicate the subgingival pathogens and halt 
the inflammatory cascade(Herrera, Matesanz, Bascones-Martinez, & Sanz, 
2012). Systemic administration of antibiotics can result in side effects of 
inadequate concentration of the drug reaching the periodontal pockets and 
developing microbial resistance. Hence, local delivery systems have the 
advantage of direct access to disease site bypassing the systemic route and 
enhancing the efficacy of the drug.(Garg, Singh, Arora, & Murthy, 2012). 
Therapeutic approaches that can target the periodontal pathogens specifically 
are lacking.  
 
Using the premise of nanotechnology, non-toxic electrospun fibers can be 
fabricated to administer BAR peptide locally as they offer several 
advantages. The small fiber size can help the drug be delivered to the 
appropriate site (Ferrari, 2004). They have open and interconnected pores, 
allowing for optimal interaction with bioactive molecules and have sufficient 
binding affinity to allow release of the encapsulated drug.(Morie, Garg, 
Goyal, & Rath, 2016). This project focuses on the synthesis of BAR-





Electrospinning is a relatively simple, user-friendly and inexpensive process 
used to fabricate fibers. It is an established technique used to produce small 
diameter fibers in the range of several nanometers to micrometers. Since the 
advent of using electrostatic forces to produce fibers in the 1930s (Formhals 
A., 1934) it has gained popularity. Specifically, during the last 20 years it has 
been employed to fabricate products for use in medical applications, 
including fiber drug delivery systems and tissue engineering scaffolds. 
Reasons such as being easy to handle, minimum consumption of solution, 
enabling controllable fiber diameter, processing convenience, providing a 
cost effective method, in parallel with process reproducibility make 
electrospinning the method of choice for large scale preparation of fibers 
(Thenmozhi, Dharmaraj, Kadirvelu, & Kim, 2017). The electrospinning 
process converts polymeric solution into solid fibers by application of 
electrical force. The many advantages of electrospinning include high 
loading capacity, high encapsulation efficiency, simultaneous delivery of 
diverse active agents, ease of operation, and cost-effectiveness (Wang, 
Wang, Yin, & Yu, 2010). Electrospun fibers have been successfully used to 
achieve different drug release profiles, such as immediate, smooth, pulsatile, 
delayed, and biphasic releases (Prabaharan, Jayakumar, & Nair, 2012). 
Moreover, drugs ranging from antibiotics and anticancer agents to proteins, 
aptamer, DNA, and RNA have been incorporated into electrospun fibers 
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(Prabaharan et al., 2012). As shown in figure 2, the apparatus consists of a 
high voltage power supply, syringe pump, syringe needle and a stainless steel 
rotating mandrel as a metal collector. The main governing forces are 
electromechanical and hydrodynamic forces, and its working principle is 
based on when very high voltage supply applied on a polymer solution, 
which induces charge within the polymer and needle. When the charge 
repulsion force exceeds the surface tension, a jet is splayed from the needle 
tip (referred to as a “Taylor cone”) creating droplets with very high surface 
area (Goyal, Macri, Kaplan, & Kohn, 2016; Thakkar & Misra, 2017). As the 
strand of solution travels to the collector, the solvent evaporates to leave 
fibers.  
 
Figure 2. Overall setup of standard horizontal electrospinning setup 
including a syringe pump, polymer-drug/peptide solution, high voltage 




In this study, we describe an approach to fabricate fibers encapsulated with 
BAR peptide to provide short-term release of the peptide via uniaxial/blend 
electrospinning. In uniaxial/blend electrospinning, a single nozzle syringe is 
used to electrospin polymer-solvent or polymer-solution combinations into 
solid porous fibers. Electrospinning is a simple approach in which water-
soluble bioactive agents such as proteins, peptides, nucleic acids and also 
hydrophilic/hydrophobic drugs are combined into polymer solutions 
containing aqueous or organic solvents prior to electrospinning.  
 
 
Figure 3. A schematic representation of blend electrospinning strategy to 
formulate electrospun fibers and the expected distribution of the bioactive 
molecules in the fibers. 
 
The electrospinning process localizes biomolecules within the fibers of the 
scaffolds rather than simply adsorbing them to the scaffold surface. As such, 
this approach has the capability to improve  sustained-release relative to 
physical adsorption (Wei Ji et al., 2011). Also compared to co-axial 
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electrospinning, uniaxial spinning is relatively a simpler method with no 
additional setup required to fabricate fibers. In this work, we adopt this 
straightforward approach by combining the BAR peptide solubilized in an 
aqueous solution (Tris-EDTA, TE) buffer and with an organic solvent blend 
(dimethyl sulfoxide, DMSO/chloroform) that contains polymer solution. 
 
Electrospun fibers 
Electrospinning is a versatile method to fabricate fibers that have diameters 
ranging from several nanometers to micrometers. Molecules such as proteins, 
peptide, antibodies, and small molecule drugs, can be loaded within or on the 
surface of fibers according to their properties. Using electrospun fibers as 
drug delivery systems provides many advantages including a) high drug 
loading (up to 60%) and encapsulation efficiency (up to 100%) so the drug 
is released continuously for longer duration upon insertion in the body (Ball 
& Woodrow, 2014), b) polymer diversity to accommodate compatibility with 
physico-chemically distinct agents (Ball, Krogstad, Chaowanachan, & 
Woodrow, 2012), c) easy modulation of drug release profile depending upon 
the properties of polymer/polymeric blends/other materials used (Sundararaj, 
Thomas, Peyyala, Dziubla, & Puleo, 2013), and d) process simplicity and 
cost-effectiveness (Ball, C., & Woodrow, K. A., 2014). These fibers possess 
high surface to volume ratio which would accelerate the solubility of the drug 
in the aqueous solution and enhance the efficiency of the drug (Meng et al., 
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2011). With a high degree of structural perfection and resultant superior 
mechanical properties (Liao, Zhang, Gao, Zhu, & Fong, 2008) electrospun 
fibers have open and interconnected pores which allow for optimal 
interaction with bioactive molecules, have excellent ability to deliver the 
encapsulated substances to the target site and have sufficient binding affinity 
to allow release of the encapsulated substance for longer duration (Morie et 
al., 2016). Many studies have shown that fibers comprised of polymer blends 
have a great potential for tuning drug miscibility and the resulting drug-
polymer interactions could lead to different release profiles (Chou & 
Woodrow, 2017). 
 A number of natural, synthetic, semi synthetic and biological polymers are 
used. Since biocompatible, biodegradable, and Food and Drug 
Administration (FDA) approved polymers including PLGA (W. J. Li, 
Laurencin, Caterson, Tuan, & Ko, 2002), PCL (59),PLLA (Jun, Hou, 
Schaper, H. Wendorff, & Greiner, 2003) and PEO (Son, Youk, Lee, & Park, 
2004) have been successfully electrospun into fibers, all the mentioned 





HYPOTHESIS AND SPECIFIC AIMS 
 
Research Hypothesis 
We hypothesize that BAR-encapsulated EFs, will provide short-term release 
of therapeutically relevant concentrations of BAR. Moreover, we 
hypothesize that BAR release from EFs may be modulated by changing 
hydrophilic:hydrophobic polymeric fiber blend ratios. Long-term, we 
believe EFs will offer a new dosage form in which to encapsulate BAR, and 
will function as an effective drug delivery vehicle within the oral cavity. 
Specific Aims 
1. Synthesize electrospun fibers (EFs) in different formulations that 
encapsulate BAR peptide. 
2. Characterize the electrospun fibers (EFs) to provide release of the 
peptide for up to 24 hr. 
 






MATERIALS AND METHODS 
Peptide Synthesis 
The peptide used in this study (shown in Table 1) was synthesized by 
BioSynthesis, Inc. (Lewisville, TX). It was obtained with a purity greater 
than 85% and comprised residues 1167 to 1193 of the SspB (Antigen I/II) 
protein sequence of S. gordonii.  
Table 1 Sequence of BAR peptide.  







A fluorescent BAR peptide (F-BAR), synthesized by covalently attaching 6-
carboxyfluorescein (Flc) to the epsilon amine of the lysine residue 
(underlined in Table 1), was used to determine the amount of BAR peptide 




Hydrophobic polymers including poly (lactic-co-glycolic acid) (PLGA, 
50:50 lactic:glycolic acid, MW 30,000-60,000),  methoxy-poly(ethylene 
glycol) (mPEG-PLGA, MW 5,000:55,000), polycaprolactone (PCL, MW 
80,000), and poly(L-lactic acid) (PLLA, MW 50,000)  and the hydrophilic 
polymer, polyethylene oxide (PEO, MW 100,000) were purchased from 
Sigma-Aldrich (St.Louis, MO, USA). Tris-EDTA (TE) buffer (pH 8.0), 
phosphate buffered saline (PBS) and the organic solvents chloroform, 
dimethyl sulfoxide (DMSO) and hexafluoroisopropanol (HFIP) were also 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals were 
used directly without further purification. One milliliter plastic syringes, petri 
dishes, and 20 ml scintillation vials were obtained from VWR. One ml glass 
syringes were purchased from Fisher Scientific. The electrospinner was 
provided courtesy of Dr. Stuart Williams at the Cardiovascular Innovative 
Institute, University of Louisville. 
Preparation of Polymer solutions 
To prepare the hydrophobic polymer batches, PLGA, mPEG-PLGA, and 
PLLA were dissolved in HFIP at a concentration of 15% (w/w). This solution 
was aspirated into a 7 ml glass scintillation vial, and sealed using parafilm to 
prevent evaporation of the organic solvent. Keeping the vial at eye level, the 
level of the polymer solution was marked to ensure a constant volume of 
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organic solvent was maintained post-incubation. The vial was placed in a 
shaker at 150 rpm and incubated at 37°C overnight to solubilize the polymer. 
The final volume of the polymer solution was 1 ml. The following day, BAR 
peptide was dissolved in 200 µl TE buffer in a 1 ml eppendorf tube and 
vortexed for 5 minutes. The BAR solution was mixed with the polymer 
solvent at a concentration of 1% (w/w), followed by vortexing the 
polymer/BAR solution for another 5 minutes. 
To prepare blended polymers, the hydrophobic polymers PLGA, PCL and 
PLLA were mixed with PEO at different ratios (40:60, 20:80, 10:90) in (w/w) 
to form PLGA/PEO, PCL/PEO, and PLLA/PEO blends in chloroform at a 
concentration of 15% (w/v). The blended solutions were aspirated into a 20 
ml glass scintillation vial, and sealed using parafilm to prevent evaporation 
of the organic solvent. Keeping the vial at eye level, the solvent meniscus 
was marked to ensure a constant volume of organic solvent was maintained 
post-incubation. If any solvent evaporated during incubation, the marking 
was used to add fresh solvent to maintain the original solvent volume. The 
vial was placed in a shaker at 150 rpm and incubated at 37°C overnight to 
solubilize the polymer. The final volume of the polymer solution was 1ml. 
The following day, BAR peptide was dissolved in 60 µl DMSO in a 1 ml 
eppendorf tube and vortexed for 5 minutes. The BAR solution was mixed 
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with the polymer solvent at a concentration of 1% (w/w), followed by 
vortexing the polymer/BAR solution for another 5 minutes. 
Electrospinning  
The experimental set-up used for conducting electrospinning included a high 
voltage power supply, syringe pump, 1ml plastic and glass syringe needle 
and a 4 mm metal mandrel.  
On the day of synthesis, the plexiglass case of the electrospinner was opened 
to adjust the position of the collector. A 4 mm diameter stainless steel 
mandrel was cleaned using sand paper to remove residue and was secured to 
the collector. For the non-blended polymer solution with HFIP as the solvent 
once the BAR peptide solution was mixed, 1 ml of this solution was loaded 
into a 1ml plastic syringe with an 18-gauge needle tip. The syringe was held 
upright for a few minutes and pushed gently to let the air bubbles out. The 
syringe was then mounted on the syringe pump, setting the holder plate on 
top of syringe to keep it in place. The inner diameter of the syringe pump 
program was set to the internal diameter of the BD plastic syringe (4.78 mm). 
The needle tip was pushed into the circular hole until the tip was roughly 1 
inch into plexiglass case, and centered. The collector was adjusted such that 
there was at least 10 cm distance maintained from the needle tip.  The 
alligator clip from the voltage source was attached to the needle tip 1 inch 
away from syringe but still outside the plexiglass case. The syringe pump 
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motor controls were adjusted by setting the “slide” control to 4.5 and the 
“rotor” to 8.  The voltage supply was set at 20 kV, and the syringe pump flow 
rate was set to 0.8 ml per hour. The polymer solution was electrospun at room 
temperature, under atmospheric conditions, for 1 hr 15 min, and the resulting 
fine mist of solution was collected on the mandrel and allowed to dry for 15 
minutes. The mandrel was removed from the collector and using a razor 
blade, the fiber was cut and gently peeled off the mandrel. The fiber was 
placed in a labeled petri dish and kept in desiccator for 24 hr before any 
characterization (weighing) occurs, preventing residual solvent from 
contributing to the fiber weight. The desiccated fibers were stored in 4°C 
until use. 
For the blended polymer solution with BAR peptide, 1 ml of the solution was 
aspirated into a 1 ml glass syringe with a 22-guage metal blunt needle and 
mounted on the automated syringe pump. The internal diameter of the 
Hamilton Gastight syringe was set to 4.61 mm. A distance of 15 cm was kept 
between the needle tip and the collector. The “slide” control was set to 4.5 
and the “rotor” was set to 8.  A voltage of 20-25 kV was applied, at a flow 
rate of 0.3 ml per hr. The electrospinning processes were employed under 
ambient conditions for 3 hr 20 min. The stretched and solidified polymeric 
fibers were collected on a 4mm diameter stainless steel mandrel and allowed 
to dry for 15 minutes. The fiber was peeled off the mandrel and placed in 
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petri dish and kept in desiccator for 24 hours. After desiccation the fibers 
were stored in 4°C. 
 
Figure 4. Schematic of drug/peptide loading method within the electrospun 
fiber and its proposed release kinetics. 
 
Characterization of electrospun fibers 
Functional Characterization  
Encapsulation efficiency of BAR peptide in fibers. 
The loading and encapsulation efficiency of the peptide in the non-blended 
and blended fibers were determined by dissolving F-BAR fiber scaffolds in 
DMSO. A clean razor blade was used to cut three samples of each fiber, each 
weighing ~ 2-3 mg. The fiber samples were placed in a 1.5 ml eppendorf tube 
and DMSO was added to create a 1mg/ml solution. The samples were 
vortexed one minute, sonicated for 5 min, and left to dissolve for 1 hour in 
the dark.  
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A standard curve of F-BAR was obtained by making a 0.1 mg/ml F-BAR 
stock solution in 1:9 DMSO:TE. The stock solution was serially diluted with 
1:9 DMSO:TE to generate a concentration ranging from 0.0007 mg/ml to 0.1 
mg/ml. The diluted solutions were transferred to a 96-well clear bottom 
microtiter plate in triplicate, consisting of 100µl in each well. 
After the incubation period, the sample solutions were vortexed and 
sonicated again.  The solutions were diluted 1:2, 1:5, 1:10 and 1:100 with 1:9 
DMSO:TE solution, and transferred to a microtiter plate. 
The diluted fiber samples and standard were measured for fluorescence at 
488nm/520nm (excitation/emission) using a spectrophotometer. The amount 
of BAR peptide encapsulated in fibers was determined from the known 
standard curve of the BAR peptide. The loading and encapsulation efficiency 
of the BAR peptide in the fiber were calculated by taking the average of the 
values obtained in each dilution (1:2, 1:5, 1:10 and 1:100) of the fiber 
samples. 
Determination of peptide release profiles from fibers 
Three samples for each of the non-blended and blended fibers each weighing 
2-3 mg, were placed in clean 1.5 ml eppendorf tube. One milliliter of 1x PBS 
(pH 7.4) was added to the eppendorf tube. The fiber samples were placed in 
an incubator shaker at 130 rpm and 37°C for 1 hr. The supernatant was 
subsequently removed and pipetted into cluster tubes arranged in a freezer 
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box. To the remaining fiber in the Eppendorf tube, fresh 1x PBS was added 
and incubated until the next time point. This procedure was repeated and 
supernatants were obtained at 1, 2, 4, 8, 12, and 24 hr time points. The freezer 
box was parafilmed and covered in aluminum foil and stored at -20°C.  
A standard curve of the F-BAR was obtained and plotted by making a 1 
mg/ml F-BAR stock solution with TE buffer. This stock solution was serially 
diluted with TE buffer to generate a standard curve ranging from 0.03 µg/ml 
to 1000 µg/ml. One hundred microliters of the standard samples were 
transferred to each well of a 96-well clear bottom microtiter plate. 
The supernatants at every time point of each fiber sample and the standard 
were measured for fluorescence at 488nm/520nm (excitation/emission) 
using a spectrophotometer.  The amount of F-BAR released at each time 
point was measured by comparing to a known standard of F-BAR in TE 






Previous studies have demonstrated that EFs have been effectively used to 
deliver of proteins (Casper, Yamaguchi, Kiick, & Rabolt, 2005; Chew, Wen, 
Yim, & Leong, 2005; Xiaoqiang Li et al., 2010; Puhl, Li, Meinel, & 
Germershaus, 2014; Zeng et al., 2005). In this study we tested various 
formulations of the electrospun fibers using different polymers to deliver the 
BAR peptide. Initially non-blended EFs were fabricated using hydrophobic 
polymers PLGA, mPEG-PLGA, PLLA with HFIP (15% w/w). PCL/HFIP 
solution at 15% w/w was highly viscous and was not electrospinnable, hence 
a 12% w/w of PCL:HFIP was used.  
PLGA, PCL, PLLA were also blended in 40:60, 20:80, 10:90 w/w ratio with 
hydrophilic polymer PEO and dissolved in chloroform (15% w/v).  All 
blends were theoretically loaded with 1% w/w F-BAR: polymer, such that 
10 µg of F-BAR was loaded for every milligram polymer. The loading and 
encapsulation efficiency were determined by assessing the fluorescence of 
the dissolved polymers. The total fluorescence emitted by the dissolved EF 
solution was converted to a concentration of BAR by comparing to the 
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fluorescence of a known F-BAR standard (in 1:9 DMSO:TE buffer). Figure 
5 shows the standard curve of free F-BAR that was used to quantify the 
concentration of F-BAR in fibers.  
 
Figure 5. Standard Curve for free F-BAR showing increased fluorescence 
with an increase in F-BAR concentration. This graph was used to calculate 
the output concentration of F-BAR for BAR-EFs. The x-axis represents the 
concentration of BAR in mg/ml and the y-axis represents the fluorescence in 


















59.0 6.9 ± 0.1 68.6 ± 2.5 
mPEG-PLGA 52.0 9.4 ± 0.4 94 ± 0.5 
PCL 51.0 6.0 ± 0.4 60 ± 4.0 






























82.9 7.4 ± 0.5 74 ± 5.5 
PCL:PEO 91.5 8.6 ± 0.2 86 ± 2.4 




80.9 8.8 ± 0.2 88 ± 2.6 
PCL:PEO 89.3 8.9 ± 0.4 89 ± 4.0 





82.8 8.8 ± 0.5 88 ± 5.6 
PCL:PEO 80 6.0 ± 0.4 60 ± 4.0 
PLLA:PEO 80.9 8.5 ± 0.3 85 ± 3.5 
 
Table 2. The amount of BAR (mg) loaded in non-blended and blended 
polymeric EF formulations (µg/mg). High loading capacity and 
encapsulation efficiency was achieved by all fiber formulations. Non-
blended EFs showed comparatively lower polymer yield than the blended 
EFs. 
 
As summarized in Table 2, the total payload for non-blended and blended 
EFs ranged from 4.6 – 9.4 µg/mg and 6.0– 9.2 µg/mg, respectively, 
indicating that high loading of F-BAR was achieved in all fiber formulations. 
The amount of polymer incorporated into the electrospun fiber scaffold, 
calculated as the overall polymer yield, ranged from 40-60% for the non-
blended formula, while the blended fibers achieved higher polymer yields ( 
80-90%).    
BAR release from BAR encapsulated EFs 
To determine the release profiles of the fiber formulations, aliquots of BAR-
encapsulated EFs were incubated in PBS at 37°C. Fluorescence of the 
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collected supernatant was measured at 1, 2, 4, 8, 12 and 24 hr. Triplicate 
fluorescence readings at each time point were compared to a known standard 
of the F-BAR in PBS. Figure 6 shows the cumulative release of BAR from 
non-blended EFs at each time point over a 24 hr duration. PLGA and mPEG-
PLGA illustrates a slow release of 9.5% and 7% respectively at 24 hr. PCL 
and PLLA fibers showed much less release of BAR for the same duration, 
with hydrophobic-only fibers demonstrating minimal release relative to the 
PEO-blended EFs. Figure 7 shows the release of F-BAR from PLGA:PEO, 
PCL:PEO and PLLA:PEO blended fibers with different blend ratios (40:60, 
80:20, 90:10). The hydrophobic fibers comprised of PLGA, mPEG-PLGA, 
PCL and PLLA only, released minimal concentrations of BAR within 24 hr, 
relative to PEO-blended fibers. Fibers comprised of 10:90 PLGA:PEO  
released 8.25 µg/mg, corresponding to 93% of the encapsulated F-BAR 
within the first 2 hr., and the highest among all the formulations. PLLA:PEO 
and PCL:PEO 10:90 fibers released 65% and 45% of F-BAR, respectively, 
within 2 hr. For the remainder of the time points, there was significant 
reduction in the release of BAR. For the 20:80 blended formulations, the 
PLGA:PEO fibers showed maximum release of 88%, compared to 
PLLA:PEO and PCL:PEO at 58% and 25%, respectively, after 2 hr. Similar 
trends in BAR release were observed for the 40:60 formulations with 
PLGA:PEO exhibiting the maximum release of 78%, with PLLA:PEO at 
45% and PCL:PEO at 17% after 2 hr. 
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Figure 6. The cumulative release of F-BAR from 1% w/w F-BAR non-
blended (100:0) PLGA, mPEG, PCL and PLLA fibers. The cumulative 
release is reported as (A) µg F-BAR per mg of fiber, and (B) percent of total 
loaded F-BAR. PLGA and mPEG-PLGA showed the greatest release of 
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Figure 7. The cumulative release of F-BAR from 1% w/w F-BAR blended 
PLGA:PEO, PCL:PEO and PLLA:PEO fibers (A) 40:60, (B) 20:80, and 
(C) 10:90. The cumulative release is reported as both µg F-BAR per mg of 
fiber on the left axis, and as the percent of total loaded F-BAR on the right 
axis.  
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Figure 8. The cumulative release of F-BAR from the hydrophobic non-
blended and PEO-blended formulations as a function of hydrophobic 
polymer type (PLGA, PCL, or PLLA) and PEO ratio in each blend. The 
release of encapsulated BAR increases with an increase in PEO fraction. 
PLGA and PEO blends exhibit the most significant and rapid F-BAR release, 
relative to PLLA and PCL blends. For all polymer types, the 10:90 blends 
show the greatest peptide release as compared to 20:80 and 40:60 
formulations at any given time point. PLGA:PEO (10:90) fibers provide the 




Figure 8 shows the importance of the PEO ratio in the each hydrophobic fiber 
type, with the 10:90 formulation showing maximum release for each 
hydrophobic blend. The 40:60 PLGA:PEO, PLLA:PEO and PCL:PEO 
released the least BAR (78%, 45% and 17% respectively) within the first 2 
hours.  The release trends for the polymer blends of different ratios were 
similar, with PLGA blends achieving the highest BAR release, followed by 







Periodontal disease is one of the most widespread oral diseases among the 
adult population worldwide, resulting in degradation of the supporting 
tissues of the teeth, thereby producing aesthetic and functional problems for 
the patient. A key feature of this inflammatory disease is dependent on the 
complex microbiome residing in the oral cavity. With a complex, 
polymicrobial etiology, it was shown that ‘red complex’, gram-negative 
anaerobic bacteria like Porphyromonas gingivalis, Treponema denticola, 
Tannerella forsythia, and Filifactor alocis were some of the species 
present in the pathogenic dental plaque and strongly associated with 
disease (Griffen et al., 2012; Socransky et al., 1998). Formation of deep 
periodontal pockets, and the persistence of subgingival plaque caused by 
adhesion and colonization of bacteria via contact dependent signaling 





Porphyromonas gingivalis, being a prominent component of the oral 
microbiome and a successful colonizer of the oral epithelium (Yilmaz, 2008), 
has been suggested to function as a keystone pathogen, as it facilitates a 
change in both the amount and composition of the normal oral microbiota 
and creates dysbiosis between the host and dental plaque (Darveau et al., 
2012). Before it resides in the subgingival pockets as an obligate anaerobe, 
its initial colonization occurs with oral commensals in the aerobic 
supragingival environment. The initial species-specific supragingival 
interaction between P. gingivalis and S. gordonii is considered to initiate the 
biofilm formation process (Kolenbrander & London, 1993). It is mediated by 
Mfa1 of P. gingivalis and SspB polypeptide of S. gordonii (Carlo Amorin 
Daep et al., 2006). Hence P. gingivalis is being targeted as a significant 
organism to inhibit biofilm formation.  
 
A synthetic analog of the SspB polypeptide designated, SspB Adhering 
Region (BAR), was identified (C. A. Daep et al., 2006), providing a species-
specific target that was successful in limiting P. gingivalis colonization both 
in vitro and in vivo. While BAR was successful in limiting P. gingivalis 
colonization both in vitro and in vivo, it was shown to be less effective against 
well-established and complex biofilms. Previous work has revealed that 
BAR potently inhibits the formation of two-species biofilms, but it is less 
effective in disrupting established or more complex biofilms, requiring 
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higher concentrations and prolonged exposure to be effective. The objective 
of this project was to synthesize and characterize EFs as a new dosage from 
alternative to deliver the bioactive molecule, BAR. Fibers as a delivery 
platform to the oral cavity may protect and sustain the delivery of BAR for 
oral administration, and provide a mechanism to improve the therapeutic 
outcomes by increasing the localized concentration of BAR. In this work, we 
hypothesized that BAR-encapsulated EFs, will provide short-term release of 
therapeutically-relevant concentrations of BAR and that BAR release from 
EFs may be modulated by changing polymeric fiber blend ratios.  
Local drug delivery carriers in the form of films (Shifrovitch, Binderman, 
Bahar, Berdicevsky, & Zilberman, 2009), strips (Friesen, Williams, Krause, 
& Killoy, 2002; Leung, Jin, Yau, Sun, & Corbet, 2005), and wafers 
(Bromberg et al., 2000) have been applied for periodontal disease, where the 
subgingival pockets act as a natural reservoir for these drug loaded devices. 
However, the methods used in the fabrication of these dosage forms include 
solvent casting, melt spinning and direct milling methods. These procedures 
are labor intensive, time consuming, and expensive. In contrast, the 
electrospinning method provides a simple to use, time and cost efficient 
process. The EFs also offer several advantages compared with other dosage 
forms including the large surface-to-volume ratio for better contact of the 
encapsulated bioactive molecule to the surrounding medium, small diameter 
fibers for efficient drug release, ability to tailor the drug release profile, 
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mechanical stability, and ease of fabrication for similar application (Su, Li, 
Tan, Chen, & Xiumei, 2009). 
Electrospun fibers have been used as a delivery vehicle in several biomedical 
applications. Some examples of their applications include utilization as 
wound dressing materials, due to their unique composition and morphology 
that mimics the extracellular matrix (R. Chen J.A. Hunt, 2007). For tissue 
regeneration purposes − where many polymers have been electrospun with 
PCL and PLGA into fibrous membranes for Guided Tissue Regeneration in 
periodontics (GTR) (Inanc, Arslan, Seker, Elcin, & Elcin, 2009; Yang, Both, 
Yang, Walboomers, & Jansen, 2009) and as drug delivery vehicles for 
bioactive molecules, antimicrobial agents, anti-inflammatory drugs, and 
anesthetics. Studies have used human periodontal ligament (hPDL) cells 
seeded on PLGA EFs (Inanc et al., 2009), in combination with PCL and PLA 
to deliver doxycycline (Chaturvedi, Srivastava, Srivastava, Gupta, & Verma, 
2013) and metronidazole (Reise et al., 2012), respectively. Similarly, we 
hypothesized that fibers that incorporated BAR peptide may be used to 
facilitate delivery and enhance the local concentration of BAR in the oral 
cavity.  
Moreover, research by Kim et al, indicated that blending hydrophobic with 
more hydrophilic polymers increased the release of lysozyme, while 
maintaining lysozyme activity. Many studies also have shown the addition 
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of PEO into the protein solution can be beneficial for improving protein 
stability (Casper et al., 2005; C. Li, Vepari, Jin, Kim, & Kaplan, 2006; Y. Li, 
Jiang, & Zhu, 2008). Given the favorable properties of the polymers 
mentioned, we successfully synthesized the electrospun fibers encapsulating 
the BAR using uniaxial-blend electrospinning technique for both the non-
blended and blended formulations. To demonstrate the functionality of BAR-
incorporated fibers, we initially formulated a 1% w/w of BAR:polymer, 
resulting in a theoretical loading of 10 g BAR per mg of polymer. To 
achieve continuous release and the release of defined quantities of the 
peptide, the polymer yield and BAR encapsulation was assessed. The initial 
polymer mass, used to electrospin fibers, is required to adjust the calculation 
for F-BAR incorporation in absolute amount (ug BAR/mg polymer) and % 
efficiency. The unblended fibers, with HFIP as their solvent showed a much 
lower polymer yield ranging between 40-60% compared to blended fibers, 
suggesting that HFIP may not be the best solvent in which to synthesize 
BAR-encapsulated fibers. Chloroform-based blended fibers exhibited higher 
overall polymer yield in comparison, indicating chloroform as the preferred 
solvent to formulate BAR encapsulated fibers.  
With respect to BAR encapsulation, all the resulting EFs displayed high BAR 
payload, ranging from 4.7 to 9.4 µg/mg and high encapsulation efficiency 
ranging from 60-90%. To further evaluate effective fiber formulations for 
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BAR, release kinetics of the non-blended and blended fibers were assessed. 
The cumulative release of BAR from the fibers was expressed as µg/mg and 
% total, and calculated as the concentration of the BAR in the release media 
relative to the actual concentration of BAR in the fibers. The release data of 
the unblended fibers revealed minimal release of 9.5%, 7%, 1.5% and 1.4% 
from PLGA, mPEG-PLGA, PLLA and PCL fibers respectively over a 
duration of 24 hr. The high hydrophobicity of the non-blended fibers of 
PLGA, PCL and PLLA likely enables release eluent to penetrate only the 
outermost layer of fibers, resulting in the rapid release of BAR only near the 
fiber surface. 
By modulating the hydrophobicity of the fibers with the addition of 
hydrophilic PEO in ratios (40:60, 20:80 and 10:90), the release was 
significantly improved. The PLGA:PEO (10:90) fibers exhibited 90% 
release of BAR, the highest among all the blended and non-blended 
formulations within the first 2 hr, with PLLA:PEO (10:90) exhibiting 65% 
release, and PCL:PEO (10:90) releasing 45% in the same time frame. 
Negligible quanities of BAR were released after 24 hr. 
As the concentration of PEO increased, BAR release accelerated with 10:90 
ratio of PLGA/PCL/PLLA: PEO illustrating higher cumulative BAR peptide 
release percent than 20:80 and 40:60 blend fibers. Studies have shown that 
by introducing hydrophilic PEO into fiber formulations, the physical and 
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mechanical properties of the fiber change, in addition to providing the ability 
to tune encapsulant (here, BAR) release (Evrova et al., 2016). While 
hydrophobic polymers provide structural integrity to the scaffold, the PEO 
makes it more porous, caused by the dissolution of PEO in solution, enabling 
the release of the hydrophilic BAR peptide. In addition, hydrophilic 
molecules have been shown to have more affinity and compatibility with 
PEO, explaining the initial burst release presented by the blended fibers. 
Among the hydrophobic polymers utilized, PLGA formulations 
demonstrated the highest release at early time points. PLLA formulations 
with different concentrations of PEO showed much better release profiles 
than PCL fibers over the desired duration of 24 hr. We propose that PLGA 
fibers demonstrate the highest release due to its amorphous and less 
hydrophobic properties, relative to PLLA and PCL. In contrast, we propose 
that PCL:PEO fibers demonstrated the least burst release due to its crystalline 
and slightly more hydrophobic features. 
Among the formulations, though mPEG-PLGA and PLLA:PEO (40:60) 
reveals the highest encapsulation efficiency of 94% and 92%, a low release 
of 7% and 55% of the encapsulated BAR at the end of 24 hrs may not be 
effective formulations. Taking both encapsulation efficiency and release 
properties into consideration, PLGA:PEO (10:90) is considered the most 
effective formulation from this study.  
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In addition to materials properties, the electrospinning process itself can 
affect encapsulant location within the fibers, prompting different release 
kinetics. During electrospinning, the electrical force may drive BAR, to 
aggregate close to the fiber surface, due to charge repulsion (Szentivanyi, 
Chakradeo, Zernetsch, & Glasmacher, 2011). This localization may also 
contribute to burst release.  
The fibers fabricated in this study were formulated with 1% w/w 
BAR:polymer. As such, they demonstrated high encapsulation efficiency 
spanning 60-90%, with burst release in the first 2 hr and minimal release 
thereafter. To achieve the IC50 of BAR (4 µg/ml) at every time point over the 
duration of 24 hr, loading capacity may be increased. However, previous 
work has shown that using a theoretical loading higher than 1 % w/w (Kim 
et al., 2004) via uniaxial blended spinning process may still result in 
significant initial burst release. To overcome burst release, optimize the 
release kinetics, and maintain peptide stability, techniques like emulsion 
electrospinning and co-axial electrospinning may be adopted (Sebe, Szabo, 
Kallai-Szabo, & Zelko, 2015) (X. Li et al., 2010). 
Co-axial electrospinning utilizes two different capillary channels 
concentrically arranged to keep the protein solution and polymer solution 
separate creating a core and sheath morphology. The drug is trapped within 
the core, which is surrounded by a polymer shell. Several studies have shown 
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sustained-release of bioactive molecules using this methodology. Moreover, 
the bioactivity biological agents is also maintained since it is not incorporated 
into the polymer/solvent solution prior to electrospinning (W. Ji et al., 2010).  
Emulsion electrospinning adopts a similar principle, where the peptide is 
dissolved in an aqueous solution, which is then added to an immiscible 
polymer-solvent solution creating a water-in-oil type of emulsion. This 
emulsion helps to encapsulate the aqueous agents within the core, to provide 
sustained and incremental release of the encapsulant. We speculate that if the 
blended polymeric fibers are synthesized using this approach,  more 
prolonged administration of BAR may be achieved via sustained release  
In addition to the overall electrospinning technique, particular processing 
parameters have been shown to impact fiber morphology. If the distance 
between the syringe tip and collector is too close, there may not be enough 
time for the solvent to evaporate, promoting EF adhesion to the mandrel  (Z.-
M. Huang, Zhang, Kotaki, & Ramakrishna, 2003). We found the distance of 
15 cm between the needle and the collector to be ideal, when a voltage of 20-
25 kV was applied. In addition, inadequate voltages and flow rates can 
promote bead formation on the electrospun fibers, resulting in unstable and 
irreproducible fiber morphology (Sill & von Recum, 2008). 
Future studies include plans to assess the functionality of BAR encapsulated 
EFs against biofilms. Given that the more hydrophilic blended fibers released 
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higher amounts of BAR over 24 hr, relative to the non-blended fibers, we 
suggest testing the PLGA:PEO (10:90) fibers against in vitro biofilms. 
Previous work showed free soluble BAR potently inhibits P. gingivalis-S. 
gordonii biofilm formation at IC50 = 1.3µM. However, with the transient 
activity observed using free BAR, the high loading and encapsulation 
efficiency of the fibers as shown in the results, Table 2, in parallel with the 
ability to tailor the release kinetics may enable greater efficacy against 
biofilm formation and disruption.  
In this work, we demonstrated the feasibility, versatility and straightforward 
approach of blend electrospinning to prepare BAR encapsulated EFs that 
release therapeutically-relevant concentrations of BAR. Following studies 
will be focused on optimizing the release kinetics of BAR EFs and testing 
their efficacy against established and complex biofilms. This will be helpful 
in formulating long-term therapeutics for periodontitis as an intra-pocket 
delivery system, where the fibers can be immobilized in the subgingival 
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